Time filter

Source Type

Leuven, Belgium

TiGenix is a leading European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialised product. Its corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a spin-off from the Katholieke Universiteit Leuven and the Universiteit Gent.Built on solid pre-clinical and CMC packages, new stem cell products are being developed in close consultation with the European Medicines Agency . Cx601 is in Phase III of clinical development to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.The company’s commercialised product, ChondroCelect®, an autologous cell therapy product for cartilage repair in the knee, was the first Advanced Therapy Medicinal Product to be approved by the European Medicines Agency , and is marketed and distributed by Swedish Orphan Biovitrum AB and by Red Cross Blood Systems in Finland.Cell Therapy and TigenixAfter small molecules and large molecules , cell and gene therapy are the next wave of medicinal therapy development. Cell therapy is distinctive and promising for addressing unmet medical needs because it can be regenerative, that is it repairs and replaces tissue and organs which are damaged; and it can be immune-modulatory, that is it controls inflammation and can help the body to return to homeostasis . Tigenix is at the forefront of this new wave, with a marketed product and a pipeline of late stage assets. The pipeline is developed from the eASC platform, an allogeneic cell therapy model whose products are scalable and ready for use. Wikipedia.

The invention discloses a process for fabricating a biomaterial, comprising: a) joining a porous collagen based-material with a non-porous collagen based-material by applying a controlled amount of a bonding layer of a gel comprising collagen to a bonding surface of the non-porous collagen based-material, and contacting a surface of the porous collagen based-material with the gel applied to the bonding surface to partially hydrate a section of the porous material at the interface between the materials; b) drying the gel to dry to bond the materials together; and c) cross-linking the collagens in the bonding layer. Also disclosed are biomaterials and implants produced using the fabrication process.

TiGenix and Consejo Superior De Investigaciones Cientificas | Date: 2014-08-20

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subjects immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.

TiGenix and Autonomous University of Madrid | Date: 2013-09-03

Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.

TiGenix | Date: 2011-09-08

The present invention provides novel stem culture compositions and methods.

Discover hidden collaborations